/
Other
Endothelial Dysfunction
20
Pipeline Programs↗
9
Active Trials↗
17
Companies Involved↗
Endothelial Dysfunction is an emerging landscape with 20 programs across 17 companies. The most active players are Hunan Kelun Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 1
No programs
Phase 23
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
17 of 18 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.
Analysis
Trial Status
82
clinical trials
Completed48 · 59%
Unknown status18 · 22%
Terminated6 · 7%
Recruiting6 · 7%
Active, not recruiting2 · 2%
Withdrawn1 · 1%
Other1 · 1%
Clinical Trials
Trial Activity
82 trials
Vascular Endothelial Dysfunction in Sleep Apnea
Recruiting·—·Phase 1·NCT05289063·110 enrolled
Neurovascular Effects of Empagliflozin in Mid-Life and Older Adults With Prehypertension
Not yet recruiting·—·Approved·NCT07799441·100 enrolled
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
Completed·—·Phase 2/3·NCT02866214·57 enrolled
A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients
Completed·—·Phase 4·NCT00675987·53 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)